[1]麦五久代·吐尔逊 阿尔祖古丽·麦麦提 冯艳.中性粒细胞/淋巴细胞比值对老年非瓣膜性心房颤动患者心血管死亡及全因死亡的预测价值[J].心血管病学进展,2025,(3):264.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.016]
 Maiwujiudain·Tuerxun,Aerzuguli·Maimaiti,FENG Yan.Predictive Value of Neutrophil to Lymphocyte Ratio for Cardiovascular Mortality and All-Cause Mortality in Elderly Patients with Non-Valvular Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2025,(3):264.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.016]
点击复制

中性粒细胞/淋巴细胞比值对老年非瓣膜性心房颤动患者心血管死亡及全因死亡的预测价值()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2025年3期
页码:
264
栏目:
论著
出版日期:
2025-03-25

文章信息/Info

Title:
Predictive Value of Neutrophil to Lymphocyte Ratio for Cardiovascular Mortality and All-Cause Mortality in Elderly Patients with Non-Valvular Atrial Fibrillation
作者:
麦五久代·吐尔逊1 阿尔祖古丽·麦麦提2 冯艳3
(1.新疆医科大学研究生学院,新疆 乌鲁木齐 830011;2.新疆维吾尔自治区维吾尔医院心病科, 新疆 乌鲁木齐 830002;3.新疆维吾尔自治区人民医院心脏及泛血管诊疗中心,新疆 乌鲁木齐 830001)
Author(s):
Maiwujiudain·Tuerxun1Aerzuguli·Maimaiti2FENG Yan3
(1.Graduate College,Xinjiang Medical University,Urumqi 830011,Xinjiang,China; 2.Department of Cardiology,Uygur Medicine Hospital of Xinjiang Uygur Autonomous Region,Urumqi 830002,Xinjiang,China; 3.Heart and Extensive Vascular Center,People’s Hospital of Xinjiang Uygur Autonomous Region,Urumqi830001,Xinjiang,China)
关键词:
中性粒细胞/淋巴细胞比值心房颤动全因死亡心血管死亡
Keywords:
Neutrophil to lymphocyte ratioAtrial fibrillationAll-cause mortalityCardiovascular mortality
DOI:
10.16806/j.cnki.issn.1004-3934.2024.03.016
摘要:
目的 探讨中性粒细胞/淋巴细胞比值(NLR)与老年非瓣膜性心房颤动(NVAF)患者全因死亡及心血管死亡的相关性。方法 本研究采用回顾性队列研究,选取2022年1—12月就诊于新疆维吾尔自治区人民医院的老年NVAF患者为研究对象,进行生存情况的随访。采用Cox比例风险回归模型和Kaplan-Meier生存曲线评估NLR与老年NVAF患者死亡率的关系。采用限制性立方样条曲线评估NLR与死亡风险的影响,ROC曲线分析NLR的预测能力。结果 共纳入484例患者,平均随访849.44 d 。高NLR水平组患者的全因死亡及心血管死亡风险显著增加。Cox回归分析显示NLR是老年NVAF患者全因死亡的独立预测因素。NLR对老年NVAF患者死亡风险具有较好的预测能力。结论 NLR水平升高与老年NVAF患者死亡风险具有显著相关,有助于识别临床预后较差的老年NVAF患者。
Abstract:
Objective To investigate the correlation between neutrophil to lymphocyte ratio (NLR) and all-cause mortality and cardiovascular mortality in elderly patients with non-valvular atrial fibrillation (NVAF). Method This study adopted a retrospective cohort study,selecting elderly NVAF patients who visited People’s Hospital of Xinjiang Uygur Autonomous Region from January 2022 to December 2022 as the research subjects ,and conducting follow-up on their survival status. Use Cox proportional hazards regression model and Kaplan-Meier survival curve to evaluate the relationship between NLR and mortality rate in elderly NVAF patients. Using restricted cubic spline curves to evaluate the impact of NLR on mortality risk ,and analyzing the predictive ability of NLR using ROC curve . Result A total of 484 patients were included,with an average follow-up of 849.44 days. The risk of all-cause mortality and cardiovascular mortality is significantly increased in patients with high NLR levels. Cox regression analysis showed that NLR is an independent predictor of all-cause mortality in elderly NVAF patients. NLR has a good predictive ability for the mortality risk of elderly NVAF patients. Conclusion Elevated NLR levels are significantly correlated with the risk of mortality in elderly patients with NVAF,which helps identify elderly patients with poor clinical prognosis

参考文献/References:

[1]Lippi G,Sanchis-Gomar F,Cervellin G. Global epidemiology of atrial fibrillation:an increasing epidemic and public health challenge[J]. Int J Stroke,2021,16(2):217-221.

[2]Chapa DW,Akintade B,Schron E,et al. Is health-related quality of life a predictor of hospitalization or mortality among women or men with atrial fibrillation?[J]. J Cardiovasc Nurs ,2014,29(6):555-564.

[3] Hamatani Y ,Yamashita Y,Esato M,et al. Predictors for stroke and death in non-anticoagulated Asian patients with atrial fibrillation:The Fushimi Af Registry[J]. PLoS One,2015,10(11):e0142394.

[4]Pokorney SD,Piccini JP,Stevens SR,et al. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation:data from ROCKET AF[J]. J Am Heart Assoc,2016,5(3):e002197.

[5]Lane DA,Skj?th F,Lip GYH,et al. Temporal trends in incidence,prevalence,and mortality of atrial fibrillation in primary care[J]. J Am Heart Assoc,2017,6(5):e005155.

[6]Guo Y,Lip GY,Apostolakis S. Inflammation in atrial fibrillation[J]. J Am Coll Cardiol,2012,60(22):2263-2270.

[7]Hu YF,Chen YJ,Lin YJ,et al. Inflammation and the pathogenesis of atrial fibrillation[J]. Nat Rev Cardiol,2015,12(4):230-243.

[8]Wang Y,Jia SJ,Chi Z.[Relationship between the ratio of neutrophil/lymphocyte and risk stratification,prognosis in patients with non-ST-elevation acute coronary syndrome][J]. Zhonghua Yi Xue Za Zhi,2017,97(23):1784-1789.

[9]Guasti L,Dentali F,Castiglioni L,et al. Neutrophils and clinical outcomes in patients with acute coronary syndromes and/or cardiac revascularisation. A systematic review on more than 34,000 subjects[J]. Thromb Haemost,2011,106(4):591-599.

[10]Mittal M,Siddiqui MR,Tran K,et al. Reactive oxygen species in inflammation and tissue injury[J]. Antioxid Redox Signal,2014,20(7):1126-1167.

[11]January CT,Wann LS,Calkins H,et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons[J]. Circulation ,2019,140(2):e125-e151.

[12] [1] M. G .The Aging of Populations and its Economic and Social Implications[J].International Affairs, 1958(4):4.DOI:10.1093/ia/34.4.528a.

[13]Singh SM,Abdel-Qadir H,Pang A,et al. Population trends in all-cause mortality and cause specific-death with incident atrial fibrillation[J]. J Am Heart Assoc,2020,9(19):e016810.

[14]张天嵩. 疯狂统计学[J]. 临床与病理杂志,2018,38(7):1595.

[15]周支瑞. 聪明统计学[J]. 临床与病理杂志,2019,39(8):1858.

[16]Boos CJ,Lip GYH. The role of inflammation in atrial fibrillation[J]. Int J Clin Pract,2005,59(8):870-872.

[17]El Awady WS,Samy M,Al-Daydamony MM,et al. Periprocedural and clinical outcomes of percutaneous coronary intervention of chronic total occlusions in patients with low- and mid-range ejection fractions[J]. Egypt Heart J,2020,72(1):28.

[18]孙般若,邵迎红,李剑,等.?老年男性人群代谢异常与全因死亡及心血管死亡关系的分析[J]. 中华医学杂志,2014,94(12):913-918.

[19]高向向,王营忠,薛万腾,等. 中性粒细胞与淋巴细胞比值在心脑血管疾病中的研究进展[J]. 临床医学进展,2021,11(1):6.

[20]陈汝满,白亚飞,王春莉,等. 中性粒细胞/淋巴细胞比值和C反应蛋白/白蛋白比值对维持性血液透析患者全因死亡预测价值:随访5年的队列研究[J]. 中国全科医学,2024,27(35): 4397-4402.

[21]肖耀东,张啸虎,吴俊逸,等. F-NLR评分评估自发性基底节脑出血患者短期预后的临床研究[J]. 徐州医科大学学报,2024,44(3):175-180.

相似文献/References:

[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
 HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(3):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
 DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(3):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
 ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
 ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
 HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
 WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
 XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
 ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(3):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
 WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(3):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
 ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(3):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]

更新日期/Last Update: 2025-04-29